Over a year into the COVID-19 pandemic, key vulnerable populations in the United States and across the world lack access to effective vaccines. IDRI has developed technology that addresses some of the most important unmet vaccine needs. Our technology is proven to make RNA vaccines stable at room temperature for nearly a year, enables safe and highly-effective protein vaccines that provide durable protection against current and future COVID mutations, and allows for the advancement of vaccines that will be suitable for young children. These discoveries can help support the global effort to end COVID-19 and reduce the burden of the inevitable next pandemic.

Learning Objectives:

1. Understand limitations in current vaccines against SARS-CoV-2 that compromise universal access, durability and broadly protective immune responses

2. Become familiar with the technology behind self-amplifying / self-adjuvanting RNA vaccines delivered by a novel nanostructured lipid carrier, which generate potent immune responses and are stable at room temperature for nearly a year

3. Explore the use of vaccine adjuvant formulations as a method to generate durable and broadly-protective immune responses against coronaviruses.